Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03005 Dose-Finding Study in Major Depressive Disorder
NCT03785652Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Oct 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of toludesvenlafaxine in major depressive disorder (MDD) (5 arms), sponsored by Luye Pharma Group. Primary endpoint: 17-item Hamilton Depression Rating Scale at 6 weeks. Started Oct 2015; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03785652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785652.